BidaskClub upgraded shares of Uniqure (NASDAQ:QURE) from a sell rating to a hold rating in a research note released on Friday.

A number of other equities analysts also recently weighed in on QURE. Chardan Capital reissued a buy rating and issued a $50.00 price target on shares of Uniqure in a report on Thursday. HC Wainwright set a $42.00 price target on shares of Uniqure and gave the stock a buy rating in a report on Thursday, August 9th. Zacks Investment Research downgraded shares of Uniqure from a buy rating to a hold rating in a report on Wednesday, October 17th. Cantor Fitzgerald set a $58.00 price target on shares of Uniqure and gave the stock a buy rating in a report on Saturday, August 11th. Finally, B. Riley began coverage on shares of Uniqure in a report on Wednesday, June 27th. They issued a buy rating and a $50.00 price target on the stock. Three analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Uniqure currently has a consensus rating of Buy and an average price target of $44.90.

Shares of NASDAQ:QURE opened at $26.68 on Friday. The company has a quick ratio of 8.36, a current ratio of 8.36 and a debt-to-equity ratio of 0.06. Uniqure has a fifty-two week low of $13.71 and a fifty-two week high of $43.23.

Uniqure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.04. The company had revenue of $3.05 million for the quarter, compared to the consensus estimate of $3.37 million. Uniqure had a negative net margin of 677.98% and a negative return on equity of 72.12%. On average, analysts predict that Uniqure will post -2.44 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in QURE. OppenheimerFunds Inc. bought a new stake in Uniqure in the 2nd quarter valued at about $63,553,000. Redmile Group LLC bought a new stake in Uniqure in the 2nd quarter valued at about $61,402,000. Millennium Management LLC raised its stake in Uniqure by 242.8% in the 1st quarter. Millennium Management LLC now owns 759,585 shares of the biotechnology company’s stock valued at $17,850,000 after acquiring an additional 538,031 shares during the period. FMR LLC raised its stake in Uniqure by 16.6% in the 2nd quarter. FMR LLC now owns 3,694,681 shares of the biotechnology company’s stock valued at $139,659,000 after acquiring an additional 526,283 shares during the period. Finally, Federated Investors Inc. PA raised its stake in Uniqure by 18.9% in the 2nd quarter. Federated Investors Inc. PA now owns 1,091,280 shares of the biotechnology company’s stock valued at $41,250,000 after acquiring an additional 173,281 shares during the period. Institutional investors and hedge funds own 59.13% of the company’s stock.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Read More: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.